A Wall Street analyst who was on the sidelines of Netflix stock during its big run-up in the past year has finally turned ...

Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 5 years ago, it would be worth $2,026.90 today based on a ...

The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year. The ...

Featured Earnings AT&T Inc. (NYSE:T) (Q4) EPS of 48 cents, compared to 54 cents in the prior-year quarter. Brown & Brown, Inc ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $170.67 which represents a slight increase of $1.47 or 0.87% from the prior close of $169.2. The stock opened at $170.46 and touched a ...

Researchers from the University of Pittsburgh School of Medicine have linked pulmonary arterial hypertension (PAH), a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target ...

Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and ...